All In Biotech

Drug Trial Radar · NCT06151574

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 428 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

428

Actual

Start

Feb 9, 2024

Primary completion

Dec 10, 2026

Study completion Jan 28, 2028

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy. Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein. Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. Some visits may be conducted remotely later in the study if approved by the study doctor. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.

Conditions

  • Lung Cancer, Non-squamous, Non-small Cell

Interventions

  • zongertinibDrug

    zongertinib

  • pembrolizumabDrug

    pembrolizumab

  • cisplatinDrug

    platinum-pemetrexed chemotherapy

  • carboplatinDrug

    platinum-pemetrexed chemotherapy

  • pemetrexedDrug

    platinum-pemetrexed chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 determined by blinded central independent reviewTime frame: up to 4 years and 5 months

Locations

163 sites in 26 countries. Site status is shown where the registry gives one.

  • Clearview Cancer Institute

    Huntsville, Alabama

  • Pioneer Research Center - Bullhead City

    Bullhead City, Arizona

  • Precision NextGen Oncology

    Beverly Hills, California

  • ClinRé 001-022 (Premier Cancer Care and Infusion Center)

    Fresno, California

  • OPN Healthcare, Inc.

    Glendale, California

  • Scripps Green Hospital

    La Jolla, California

  • Valkyrie Clinical Trials

    Los Angeles, California

  • Sharp Memorial Hospital

    San Diego, California

  • St. Louis Cancer Care, LLP

    Bridgeton, Missouri

  • Oncology Hematology Associates

    Springfield, Missouri

  • Cancer Care Specialists

    Reno, Nevada

  • Northwell Health

    Lake Success, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Regional Medical Oncology Center

    Wilson, North Carolina

  • Gabrail Cancer Center

    Canton, Ohio

  • Carolina Blood and Cancer Care Associates, PA

    Rock Hill, South Carolina

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Swedish Cancer Institute

    Edmonds, Washington

  • Swedish Cancer Institute

    Issaquah, Washington

  • Swedish Cancer Institute

    Seattle, Washington

  • Clinica Adventista Belgrano

    CABA, Argentina

  • Instituto Medico Especializado Alexander Fleming

    Ciudad Autónoma de Bs As, Argentina

  • Instituto Oncologico de Cordoba

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, Argentina

  • Instituto Medico de la Fundacion Estudios Clinicos

    Rosario, Argentina

  • Prince of Wales Hospital-Randwick-66496

    Randwick, New South Wales, Australia

  • Royal North Shore Hospital-St Leonards-20807

    St Leonards, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Austin Health

    Heidelberg, Victoria, Australia

  • St John of God Subiaco Hospital

    Subiaco, Western Australia, Australia

  • Krems University Hospital

    Krems, Austria

  • Clinic Floridsdorf

    Vienna, Austria

  • Brussels - HOSP Jules Bordet

    Anderlecht, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Associacao Dr. Bartholomeu Tacchini

    Bento Gonçalves, Brazil

  • Hospital do Câncer de Londrina

    Londrina, Brazil

  • Hospital Sao Lucas da PUCRS

    Porto Alegre, Brazil

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.